Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

DISEASE CHARACTERISTICS: Diagnosis of relapsed or refractory multiple myeloma (MM) or other plasma cell disorder (PCD) At least one previous treatment for MM or PCD required PATIENT CHARACTERISTICS: Performance status ECOG 0-2 OR Karnofsky 60-100% Life expectancy At least 3 months Hematopoietic Not specified Hepatic Not specified Renal Calcium ≤ 10.5 mg/dL No renal stone formation within the past 5 years for patients who have had curative therapy for a condition associated with the risk of stones (e.g., hyperparathyroidism, bladder dysfunction, obstructive uropathy) OR had a single episode of confirmed urolithiasis No calculi in urinary tract confirmed by renal ultrasonography, kidney, ureter, and bladder (KUB) x-ray, or other imaging modality Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No uncontrolled cardiac arrhythmia Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during study and for 3 months after study completion No osteonecrosis of the jaw No history of allergic reaction attributed to compounds of similar chemical or biological composition of calcitriol, paricalcitol, or zoledronate No uncontrolled intercurrent illness that would preclude study compliance No ongoing or active infection No psychiatric illness or social situation that may preclude study compliance PRIOR CONCURRENT THERAPY: Chemotherapy More than 4 weeks since prior chemotherapy Endocrine More than 4 weeks since prior high-dose steroids Other No other concurrent investigational agents or therapies for multiple myeloma or plasma cell disorders No concurrent digoxin